Clinical Trials Sponsored by Exeltis France

Total 5747 results

Exeltis France
Insud Pharma

Completed

Benznidazole Absorption, Metabolism and Excretion Study

Healthy Male Subjects

United Kingdom
Xeltis

Recruiting

Xeltis Hemodialysis Access Graft: aXess Pivotal Study

End-stage Renal Disease

Spain, Italy, Belgium, Latvia, Portugal, Germany, Greece, United Kingdom, Poland
Xeltis

Enrolling by invitation

Xeltis Coronary Artery Bypass Graft (XABG) First in Human (FIH) (XABG-FIH)

Multi Vessel Coronary Artery Disease

Belgium, Lithuania
Xeltis

Withdrawn

Xeltis Pulmonary Valved Conduit Safety and Performance Study

Heart Defects, Congenital

Hungary, Malaysia, Poland, Slovakia
Xeltis

Not yet recruiting

Xeltis Hemodialysis Access Conduit: aXess-E Study

End Stage Renal Disease
Inmunova S.A.
Exeltis

Terminated

Phase 2/3 Study to Evaluate PK, Safety & Efficacy of INM004 in STEC Positive Pediatric Patients for Prevention of HUS

Hemolytic-Uremic Syndrome | Pediatric Kidney Disease | Bloody Diarrhea | STEC, Unspecified

Argentina
Xeltis

Active, not recruiting

First-in-Human (FIH) Study of the Xeltis Hemodialysis Access Graft (aXess-FIH)

End Stage Renal Disease | End Stage Renal Failure on Dialysis

Italy, Belgium, Latvia, Lithuania
Xeltis

Enrolling by invitation

Xeltis Bioabsorbable Pulmonary Valved Conduit Pivotal Study (Xplore2)

Heart Defect, Congenital

United States, Bulgaria, Malaysia, Poland
Xeltis

Active, not recruiting

Study to Assess Safety of the Pulmonary Valved Conduit (PV-001) in Subjects Undergoing Right Ventricular Outflow Tract Reconstruction

Congenital Heart Disease

Hungary, Malaysia, Poland
Exeltis Turkey
Monitor CRO

Completed

Evaluation of Efficacy and Safety of Gynomax® XL Ovule (Gyno-Türk)

Trichomonal Vaginitis | Bacterial Vaginosis | Candidal Vulvovaginitis | Mixed Vaginal Infections

Turkey
Exeltis Turkey
Monitor CRO

Active, not recruiting

Bioavailability Study of EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule

Bioavailability

Turkey
Xiromed LLC
Laboratorios Liconsa; Exeltis

Completed

Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD) (ARBORUS)

COPD

United States, India
Exelixis

Active, not recruiting

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy (COSMIC-312)

Hepatocellular Carcinoma

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia, Czechia, France, Georgia, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Korea, Republic of, Mexico, Netherlands, New Zealand, Philippines, ... and more
Exelixis

Active, not recruiting

Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Renal Cell Carcinoma | Head and Neck Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Castration-resistant Prostate Cancer | Urothelial Carcinoma | Differentiated Thyroid Cancer | Gastroesophageal... and other conditions

United States, Australia, Belgium, France, Germany, Italy, Netherlands, Spain, United Kingdom
Exelixis

Completed

A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (METEOR)

Renal Cell Carcinoma

United States, Belgium, Spain, Taiwan, Canada, Germany, Korea, Republic of, France, Austria, Chile, Australia, Hungary, Russian Federation, Italy, Turkey, Netherlands, Sweden, United Kingdom, Czechia, Ireland, Slovakia, Argentina, D... and more
Exelixis

Terminated

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2)

Pain | Prostatic Neoplasms | Prostate Cancer | Castration Resistant Prostate Cancer

United States, Canada, Australia, United Kingdom, Ireland
Exelixis

Terminated

Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms | Prostate Cancer | Castration Resistant Prostate Cancer

United States
Exelixis

Completed

Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects

Healthy | Hepatic Impairment

United States
Exelixis

Completed

A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function

Healthy | Renal Impairment

United States
Exelixis

Suspended

Study of XL418 in Adults With Solid Tumors

Cancer | Solid Tumors

United States
Exelixis

Recruiting

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (STELLAR-305)

Head and Neck Squamous Cell Carcinoma

United States
Exelixis

Recruiting

Study of XL309 (ISM3091) in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Exelixis

Recruiting

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (STELLAR-304)

Non-Clear Cell Renal Cell Carcinoma

United States, Spain, Korea, Republic of, Italy, Australia, France, Argentina, Brazil, Chile, Czechia, Finland, Germany, Malaysia, Netherlands, Poland, Thailand
Exelixis

Recruiting

Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002)

Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Metastatic Castration-resistant Prostate Cancer

United States, Poland, Spain, Switzerland, Austria, Australia, Belgium, Israel, Italy, New Zealand, France, Germany, United Kingdom
Exelixis

Recruiting

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

Cervical Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Epithelial Ovarian Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor-positive Breast Cancer | SCCHN | Esophageal SCC | Tissue Factor-Expressing Solid Tumors

United States, Spain, Australia, Belgium, France, Italy, Netherlands, United Kingdom, Korea, Republic of
Exelixis

Active, not recruiting

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (STELLAR-001)

Renal Cell Carcinoma | Colorectal Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor Positive Breast Carcinoma | Neoplasm Malignant

United States, Australia, Belgium, Czechia, France, Germany, Italy, Netherlands, Spain, United Kingdom
Exelixis

Completed

Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme

Glioblastoma Multiforme

United States
Exelixis

Completed

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 (COMET-1)

Pain | Prostatic Neoplasms | Prostate Cancer | Castration Resistant Prostate Cancer

Belgium, France, Italy, Canada, United States, Germany, United Kingdom, Australia, Netherlands, Spain, Austria, Ireland, Puerto Rico, Sweden
Exelixis

Terminated

A Phase 1 Study of XL019 in Adults With Polycythemia Vera

Polycythemia Vera

United States
Exelixis

Terminated

A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies

Lymphoma | Cancer

United States
Exelixis

Terminated

Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies

Lymphoma | Cancer

United States
Exelixis

Terminated

Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors

Cancer

United States
Exelixis

Completed

Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer

Cancer | NSCLC | Solid Tumors

Japan
Exelixis

Withdrawn

Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors

Cancer | Breast Cancer | Non-small-cell Lung Cancer

United States
Exelixis

Completed

Study of Multiple Doses and Regimens of XL184 (Cabozantinib) in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

Astrocytic Tumors

United States, Canada
Exelixis

Completed

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

Renal Cell Carcinoma | Papillary Thyroid Cancer | Follicular Thyroid Cancer | Huerthle Cell Thyroid Cancer

United States
Exelixis

Completed

A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib

Gastrointestinal Neoplasms | Gastrointestinal Stromal Tumors

United States
Exelixis

Completed

Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies

Lymphoma | Cancer | Thyroid Carcinoma

United States
Exelixis

Approved for marketing

Expanded Access of Cabozantinib in Medullary Thyroid Cancer

Medullary Thyroid Cancer

United States
Exelixis

Completed

Study of XL281 in Adults With Solid Tumors

Melanoma | Cancer | Colorectal Cancer | Non-small-cell Lung Cancer | Papillary Thyroid Cancer

United States
Exelixis

Terminated

A Safety Study of XL019 in Adults With Myelofibrosis

Myeloproliferative Disorders | Polycythemia Vera | Thrombocythemia, Essential | Myelofibrosis

United States
Exelixis

Terminated

Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Exelixis

Completed

Study of XL820 in Adults With Solid Tumors

Cancer

United States
Exelixis

Recruiting

Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303)

Colorectal Cancer

United States, Poland, Australia, Belgium, France, Hong Kong, Korea, Republic of, Spain, Hungary, Singapore, New Zealand, Germany, Thailand, Taiwan, Portugal, United Kingdom
Exelixis

Completed

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

Cancer | Solid Tumors

United States, Taiwan, Belgium, Israel, United Kingdom
Exelixis

Active, not recruiting

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Triple Negative Breast Cancer | Epithelial Ovarian Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor Positive Breast Carcinoma | Neoplasm Malignant

United States
Exelixis

Active, not recruiting

A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer (EXAMINER)

Medullary Thyroid Cancer

Australia, France, Israel, Spain, Russian Federation, Netherlands, Hungary, Korea, Republic of, Croatia, Italy, Canada, Poland, Romania, Sweden
Exelixis

Terminated

Study of XL114 in Subjects With Non-Hodgkin's Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Non-Hodgkin's Lymphoma (NHL) | Mantle Cell Lymphoma (MCL) | Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL)

United States
Exelixis

Active, not recruiting

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (COSMIC-313)

Renal Cell Carcinoma

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, Finland, France, Germany, Hong Kong, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, New Zealand, Poland, Singapore, Spain, Taiwan, United...
Exelixis

Completed

Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL)

Hepatocellular Carcinoma

Belgium, Hong Kong, Korea, Republic of, Canada, France, Taiwan, United States, Germany, Spain, United Kingdom, Singapore, Australia, Italy, Netherlands, Poland, Turkey, Ireland, New Zealand, Romania

Clinical Trials Sponsored by Exeltis France

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations